Insider Transactions Reported by 18 Insiders of Adicet Bio, Inc.

Symbol: ACET on Nasdaq
Location: Boston, MA

Quick Takeaways

ACET - Adicet Bio, Inc. has 18 insiders with reported activity on this page.
Net insider value flow over the last year: +$5,000,000.
Recent transaction rows are available for direct filing-level review.

What Changed

Buy value: $5,000,000; sell value: $0.
Net share flow: +5,000,000.

Why This Matters

This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.

Official SEC Source

Filed on Form 4

Issuer insider activity is sourced from SEC Forms 3, 4, and 5.

See Original Filing

Insider trading overview

Last 12 months

Net insider flow leans to buying over the last 12 months. Net value: +$5,000,000.

Buys

$5,000,000

Shares: 5,000,000

Insiders: 1

Sells

Shares: 0

Insiders: 0

Net

+$5,000,000

Shares: +5,000,000

Insiders: 1

Window (months)	Buy shares	Buy $	Sell $	Net $
0-3	0	$0	$0	$0
3-6	0	$0	$0	$0
6-9	5,000,000	$5,000,000	$0	+$5,000,000
9-12	0	$0	$0	$0

Adicet Bio, Inc. executives and other stock owners filed with the SEC include:

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
ORBIMED ADVISORS LLC	10%+ Owner	$4,490,254	+$5,000,000	+111%	Filing P/S	08 Oct 2025
Carl L. Gordon	Director, 10%+ Owner	$941,594			Mixed	21 Aug 2024
Francesco Galimi	SVP & Chief Medical Officer	$244,322			Mixed	05 Jun 2024
Aya Jakobovits	Director	$214,323			Mixed	21 Aug 2024
Lloyd Klickstein	Director	$66,225			Mixed	11 Jun 2025
Chen Schor	President & CEO, Director	$59,296			Mixed	25 Mar 2026
Brian Nicholas Harvey	Chief Financial Officer	$43,423			Mixed	25 Mar 2026
Don Healey	Chief Technology Officer	$29,134			Mixed	25 Mar 2026
Blake Aftab	Chief Scientific Officer	$25,159			Mixed	25 Mar 2026
Steve Dubin	Director	$13,847			Mixed	11 Jun 2025
Andrew Sinclair	Director	$10,797			Mixed	11 Jun 2025
Jeffrey Chodakewitz	Director	$10,797			Mixed	11 Jun 2025
Michael Kauffman	Director	$8,437			Filing P/S	21 Aug 2024
Katie Peng	Director	$7,198			Mixed	11 Jun 2025
Bastiano Sanna	Director				Mixed	14 Aug 2023
Stewart Abbot	Former Chief Scientific and Operating Officer				Mixed	11 Jun 2021
Michael Grissinger	Director				Mixed	17 Apr 2025
Julia D. Maltzman	Chief Medical Officer				Mixed	25 Mar 2026

Top shareholders of Adicet Bio, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
ORBIMED ADVISORS LLC	13D/G 3/4/5 13F	10%+ Owner · Company	9.6%	14,772,598	$11,974,668	$0	08 Oct 2025	13D/G 3/4/5 13F
RA CAPITAL MANAGEMENT, L.P.	13F 13D/G	Company	9.9% from 13D/G	948,249	$7,984,257	—	31 Dec 2025	13F 13D/G
FRANKLIN RESOURCES INC	13F 13D/G	Company	6.5% from 13D/G	626,571	$5,275,728	—	31 Dec 2025	13F 13D/G
Woodline Partners LP	13F 13D/G	Company	6.5% from 13D/G	625,000	$5,262,500	—	31 Dec 2025	13F 13D/G
VANGUARD GROUP INC	13F	Company	3%	291,277	$2,452,552	—	31 Dec 2025	13F
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	2.8%	274,375	$2,310,238	—	31 Dec 2025	13F
Prosight Management, LP	13F	Company	2.6%	250,244	$2,107,054	—	31 Dec 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	2.5%	242,945	$2,045,597	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	2.4%	234,510	$1,974,574	—	31 Dec 2025	13F
Stonepine Capital Management, LLC	13F	Company	2.3%	220,011	$1,852,493	—	31 Dec 2025	13F
Alyeska Investment Group, L.P.	13F	Company	2.1%	203,799	$1,715,988	—	31 Dec 2025	13F
Carlyle Group Inc.	13F	Company	1.9%	184,295	$1,544,391	—	31 Dec 2025	13F
ACADIAN ASSET MANAGEMENT LLC	13F	Company	1.9%	181,395	$1,525,000	—	31 Dec 2025	13F
NEXTBio Capital Management LP	13F	Company	1.6%	157,827	$1,328,903	—	31 Dec 2025	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	1.5%	144,796	$1,219,182	—	31 Dec 2025	13F
ADAR1 Capital Management, LLC	13F	Company	1.3%	128,646	$1,083,199	—	31 Dec 2025	13F
Carl L. Gordon	3/4/5	Director, 10%+ Owner	— mixed-class rows	684,857 mixed-class rows	$941,594	—	21 Aug 2024	3/4/5
TWO SIGMA ADVISERS, LP	13F	Company	1.1%	111,336	$937,449	—	31 Dec 2025	13F
CITADEL ADVISORS LLC	13F	Company	1.1%	107,814	$907,794	—	31 Dec 2025	13F
DAFNA Capital Management LLC	13F	Company	0.97%	93,812	$789,897	—	31 Dec 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.92%	88,856	$748,270	—	31 Dec 2025	13F
Burkehill Global Management, LP	13F	Company	0.64%	62,500	$526,250	—	31 Dec 2025	13F
REGENERON PHARMACEUTICALS, INC.	13F	Company	0.04%	60,511	$509,503	—	31 Dec 2025	13F
LUMINUS MANAGEMENT LLC	13F	Company	0.61%	59,558	$501,478	—	31 Dec 2025	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.58%	56,350	$474,467	—	31 Dec 2025	13F
Squarepoint Ops LLC	13F	Company	0.57%	55,723	$469,188	—	31 Dec 2025	13F
RBF Capital, LLC	13F	Company	0.4%	38,582	$324,860	—	31 Dec 2025	13F
BlackRock, Inc.	13F	Company	0.38%	36,585	$308,046	—	31 Dec 2025	13F
Maven Securities LTD	13F	Company	0.32%	31,250	$263,125	—	31 Dec 2025	13F
Francesco Galimi	3/4/5	SVP & Chief Medical Officer	— mixed-class rows	476,878 mixed-class rows	$244,322	—	05 Jun 2024	3/4/5
STATE STREET CORP	13F	Company	0.27%	25,896	$218,044	—	31 Dec 2025	13F
Aya Jakobovits	3/4/5	Director	— mixed-class rows	176,276 mixed-class rows	$214,323	—	21 Aug 2024	3/4/5
Rangeley Capital, LLC	13F	Company	0.26%	25,001	$210,508	—	31 Dec 2025	13F
BARCLAYS PLC	13F	Company	0.26%	25,000	$210,500	—	31 Dec 2025	13F
JOHNSON & JOHNSON	13F	Company	0.23%	22,779	$191,803	—	31 Dec 2025	13F
XTX Topco Ltd	13F	Company	0.19%	18,610	$156,696	—	31 Dec 2025	13F
GSA CAPITAL PARTNERS LLP	13F	Company	0.18%	17,763	$150,000	—	31 Dec 2025	13F
NORTHERN TRUST CORP	13F	Company	0.15%	14,067	$118,444	—	31 Dec 2025	13F
Lloyd Klickstein	3/4/5	Director	— mixed-class rows	134,966 mixed-class rows	$66,225	—	11 Jun 2025	3/4/5
Chen Schor	3/4/5	President & CEO, Director	— mixed-class rows	478,714 mixed-class rows	$59,296	—	25 Mar 2026	3/4/5
TANG CAPITAL MANAGEMENT LLC	13F 13D/G	Company	0.1% from 13D/G	6,158	$51,850	—	31 Dec 2025	13F 13D/G
FNY Investment Advisers, LLC	13F	Company	0.06%	6,100	$51,000	—	31 Dec 2025	13F
ROYAL BANK OF CANADA	13F	Company	0.06%	5,437	$46,000	—	31 Dec 2025	13F
Brian Nicholas Harvey	3/4/5	Chief Financial Officer	— mixed-class rows	48,506 mixed-class rows	$43,423	—	25 Mar 2026	3/4/5
UBS Group AG	13F	Company	0.04%	3,797	$31,970	—	31 Dec 2025	13F
Don Healey	3/4/5	Chief Technology Officer	— mixed-class rows	46,813 mixed-class rows	$29,134	—	25 Mar 2026	3/4/5
MORGAN STANLEY	13F	Company	0.03%	3,040	$25,597	—	31 Dec 2025	13F
Blake Aftab	3/4/5	Chief Scientific Officer	— mixed-class rows	75,536 mixed-class rows	$25,159	—	25 Mar 2026	3/4/5
Steve Dubin	3/4/5	Director	— mixed-class rows	49,100 mixed-class rows	$13,847	—	11 Jun 2025	3/4/5
BANK OF AMERICA CORP /DE/	13F	Company	0.01%	1,288	$10,845	—	31 Dec 2025	13F

Recent Insider Transactions by Companies or Individuals for Adicet Bio, Inc.

Showing up to 300 most recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership
Brian Nicholas Harvey	ACET	Stock Option (Right to Buy)	Award				43,361	43,361	25 Mar 2026	Direct
Chen Schor	ACET	Stock Option (Right to Buy)	Award				468,555	468,555	25 Mar 2026	Direct
Julia D. Maltzman	ACET	Stock Option (Right to Buy)	Award				72,555	72,555	25 Mar 2026	Direct
Don Healey	ACET	Stock Option (Right to Buy)	Award				43,361	43,361	25 Mar 2026	Direct
Blake Aftab	ACET	Stock Option (Right to Buy)	Award				72,555	72,555	25 Mar 2026	Direct
Blake Aftab	ACET	Common Stock	Tax liability	-15.2%			-535	2,981	24 Jan 2026	Direct
Don Healey	ACET	Common Stock	Tax liability	-13.4%			-535	3,452	24 Jan 2026	Direct
Brian Nicholas Harvey	ACET	Common Stock	Tax liability	-9.59%			-546	5,145	24 Jan 2026	Direct
Chen Schor	ACET	Common Stock	Tax liability	-20.5%			-1,755	6,820	24 Jan 2026	Direct
Orbimed Advisors Llc	ACET	Common Stock	Purchase	124.2%	$5,000,000	$1.00	5,000,000	9,026,359	08 Oct 2025	See footnotes
Lloyd Klickstein	ACET	Common Stock	Award	5.75%			5,900	108,566	11 Jun 2025	Direct
Lloyd Klickstein	ACET	Stock Option (Right to Buy)	Award				26,400	26,400	11 Jun 2025	Direct
Jeffrey Chodakewitz	ACET	Common Stock	Award	50%			5,900	17,700	11 Jun 2025	Direct
Jeffrey Chodakewitz	ACET	Stock Option (Right to Buy)	Award				26,400	26,400	11 Jun 2025	Direct
Steve Dubin	ACET	Common Stock	Award	35.1%			5,900	22,700	11 Jun 2025	Direct
Steve Dubin	ACET	Stock Option (Right to Buy)	Award				26,400	26,400	11 Jun 2025	Direct
Katie Peng	ACET	Common Stock	Award	100%			5,900	11,800	11 Jun 2025	Direct
Katie Peng	ACET	Stock Option (Right to Buy)	Award				26,400	26,400	11 Jun 2025	Direct
Andrew Sinclair	ACET	Common Stock	Award	50%			5,900	17,700	11 Jun 2025	Direct
Andrew Sinclair	ACET	Stock Option (Right to Buy)	Award				26,400	26,400	11 Jun 2025	Direct
Michael Grissinger	ACET	Stock Option (Right to Buy)	Award				70,200	70,200	17 Apr 2025	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.